Is COLL a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Collegium Pharmaceutical (COLL) rests on Jornay PM share gains in ADHD: Jornay PM is the main growth asset. The bear case rests on the largest risk is the pace of pain-portfolio decline. Analysts covering it publish targets from $28.00 to $60.00 against a $24.72 share price on November 20, 2026, so even the professionals disagree by 73% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
COLL key stats
At $24.72 on November 20, 2026, Collegium Pharmaceutical (COLL) has a market cap of $768M and a P/E of 22.7 on trailing earnings (3.5 on forward earnings).
- Market cap
- $768M
- P/E (trailing)
- 22.7
- P/E (forward)
- 3.5
- EPS (trailing 12 months)
- $1.09
- Price to book
- 2.6
- Beta
- 0.73
Market cap, P/E and yield are measured at the $24.72 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Collegium Pharmaceutical (COLL)?
The last two weeks for Collegium Pharmaceutical, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- COLL closed at $24.72 on November 20, 2026, down 2.4% over the past five trading days (from $25.32).
- On November 16, 2026, Barclays lowered its target to $41.00 from $48.00 (Overweight).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Collegium Pharmaceutical, based in Stoughton, Massachusetts, sells branded prescription drugs in the US. It does not discover new molecules; it buys approved brands and runs them with its own sales force. The pain portfolio covers Belbuca (buprenorphine buccal film), Xtampza ER (abuse-deterrent extended-release oxycodone) and the Nucynta franchise (tapentadol). The ADHD side came through two deals: the 2024 purchase of Ironshore, which brought Jornay PM, an evening-dosed methylphenidate, and the May 2026 purchase of Azstarys (serdexmethylphenidate and dexmethylphenidate) from Corium for about $656 million in cash plus up to $135 million in milestones. Third-quarter 2026 results, reported November 5, showed the two halves pulling in opposite directions. Net product revenue was a record $216.3 million, up about 3% from a year earlier. Jornay PM grew about 24% to $51.9 million and Azstarys added $26.5 million in its first full quarter, so ADHD products passed 36% of revenue. Pain revenue fell about 18% to $138.0 million, led by a 44% drop in Nucynta after generic and authorized-generic entry, while Xtampza ER slipped 9% and Belbuca was close to flat. Adjusted EBITDA fell about 9% to $121.6 million as operating expenses rose with the Azstarys integration, and adjusted EPS was $1.96 against $2.25 a year earlier. GAAP diluted EPS was $0.60. Management reaffirmed 2026 guidance of $825 million to $855 million in revenue and $445 million to $470 million in adjusted EBITDA. The stock closed at about $25.03 on November 20, 2026, down about 45% year to date and 43% over a year, though up about 9% over the past month, with a 52-week range of roughly $21.43 to $50.79. At that price the market values the equity near $778 million, or roughly 3.3 times trailing adjusted EPS of about $7.67. Debt is a little over $1.08 billion (about $843 million of term loans and $239 million of convertible notes) against about $145 million of cash, so enterprise value is near $1.7 billion and net leverage is about 2 times adjusted EBITDA. The valuation reflects a market that doubts the pain cash flows will last long enough, and that ADHD growth will arrive fast enough, to service the debt and replace the earnings. After the report Barclays cut its price target to $41 from $48 while keeping an Overweight rating, and the eight analysts in Yahoo Finance's count now have a mean target of about $44. Consensus for the fourth quarter is about $222 million of revenue and $1.89 of adjusted EPS.
The bull case: what would have to be true for $60.00
The most optimistic published target on COLL is $60.00, +142.7% from the $24.72 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Jornay PM share gains in ADHD
Jornay PM is the main growth asset. It is taken in the evening so the medicine is working when a child wakes up, a feature no other methylphenidate offers. Third-quarter 2026 revenue was $51.9 million, up about 24%, with prescriptions up about 16% and the prescriber base near 33,000, up 19%. Management puts its share of branded long-acting methylphenidate at about 30%, up 6.5 points in a year, and new-to-brand prescriptions were up 22% in September. Guidance for 2026 is $190 million to $200 million, against $148.9 million in 2025. Adult prescriptions, about 20% of volume, grew about 27%, which points to room beyond the pediatric base.
2. Azstarys as a second ADHD brand
Azstarys, acquired for about $656 million in cash, gives the same roughly 190-person sales force a second product to detail to the same prescribers. The call list has grown to about 27,000 doctors from 21,000 in 2025. Azstarys earned $26.5 million in the September quarter and prescriptions rose nearly 2%, a turn after a 2025 decline under the prior owner. Guidance is $65 million to $75 million for the partial 2026 year, and management expects growth to accelerate in 2027 with consumer and digital campaigns. Its patents run to about 2037, which makes it the longest-lived asset in the portfolio. Up to $135 million in milestone payments could come due if sales and manufacturing goals are met.
3. Cash generation from the pain brands
Pain revenue is shrinking but still produced $138.0 million in the quarter, and these brands carry little research cost. Belbuca, at $57.7 million, has patents running to December 2032, a court win against Alvogen, and gains about 9 million covered lives in the fourth quarter. Xtampza ER, at $45.8 million, moves to an exclusive formulary position with a payer covering about 15 million lives on January 1, 2027. Nucynta pricing after the authorized generic was stable from the second to the third quarter, management said. In October, Collegium paid GrĂ¼nenthal $17 million to settle a patent suit and end the Nucynta royalty obligation entirely, which lifts the margin on what remains of that franchise.
4. Buybacks, debt paydown and deals
Operating cash flow was $86.5 million in the third quarter, and management lists business development, debt reduction and shareholder returns as its uses. A $50 million accelerated share repurchase began in the quarter and should settle before year-end, with $100 million left on the board authorization that runs through December 2026. Share count has already fallen: about 31.1 million shares were outstanding at the start of November. With net debt near 2 times adjusted EBITDA, the company has room to buy another brand, and analysts on the call asked whether it might sell or spin the pain portfolio. Management declined to comment on any transformational deal.
The bear case: what would have to be true for $28.00
The most pessimistic published target is $28.00, +13.3% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Collegium Pharmaceutical is worth if the risks below bite instead of the drivers above.
The largest risk is the pace of pain-portfolio decline. Nucynta revenue fell 44% in a year once generics arrived, and a 2018 settlement allows Teva to sell a generic Belbuca from January 23, 2027 if it has FDA approval. Belbuca was about $222 million of 2025 revenue, so a launch would cut deeply into cash flow. Ascent Pharmaceuticals has also filed to challenge Belbuca's 2032 patent. Xtampza ER faces payer pressure. Opioid exposure brings legal risk: several dozen third-party payors sued Collegium and others in July 2026, alleging Nucynta and Xtampza ER were promoted to encourage continued prescribing, and several state attorneys general have open investigations. ADHD stimulants are Schedule II drugs, so DEA production quotas and shortages can limit supply. The balance sheet carries about $1.08 billion of debt plus a Jornay royalty obligation at about 13.5% effective interest, and cash fell from about $387 million at the end of 2025 to $145 million after the Azstarys purchase. Operating expenses rose 44% in the third quarter, and further acquisitions add integration risk. The stock is small and has been volatile, falling about 17% after the August report and about 45% so far in 2026. Analysts expect revenue of about $848 million in 2027 but adjusted EPS to fall about 5% to roughly $7.08, which reflects the Belbuca generic risk.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding COLL already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on COLL
8 analysts cover COLL, with an average target of $44.00 (+78.0% against $24.72) and a split of 7 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the COLL forecast and price target page.
How is COLL valued?
Market cap, P/E and dividend yield at today's price are in the COLL key stats above. The business figures below come from Collegium Pharmaceutical's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$815 million (+3.3% YoY in Q3)
- Q3 2026 adjusted EPS: $1.96 vs ~$1.86 consensus
- Adjusted EBITDA (TTM): ~$467 million
- Price / adjusted EPS: ~3.3x (~3.5x on 2027 consensus)
- EV / adjusted EBITDA: ~3.7x
- Total debt / cash: ~$1.08 billion / ~$145 million
As of November 2026: Figures combine the fourth quarter of 2025 with the first nine months of 2026, at a share price of about $25.03 on November 20, 2026 and about 31.1 million shares outstanding. Adjusted figures exclude large non-cash items, mainly about $55 million a quarter of amortization on acquired drug rights, which is why GAAP diluted EPS for the first nine months of 2026 was only about $0.64 and the trailing GAAP P/E is near 23. A multiple near 3 times adjusted earnings is low for a profitable drug company and shows how much the market discounts the pain brands. The $239 million of convertible notes convert at about $36.56 a share, well above the current price.
How do you decide if COLL is a buy?
Whether COLL is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold COLL indirectly through an index or sector ETF before adding more.
What would change your mind on COLL
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Jornay PM share gains in ADHD stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: the largest risk is the pace of pain-portfolio decline fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the COLL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about COLL against your real portfolio and see your actual exposure before deciding.
Your questions about Collegium Pharmaceutical
Ask Walnut's AI anything about COLL and see how it fits what you own.
FAQ
Is COLL a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Jornay PM share gains in ADHD, with revenue (ttm) at ~$815 million (+3.3% YoY in Q3). The bear case rests on the largest risk is the pace of pain-portfolio decline. Analysts covering it are spread from $28.00 to $60.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell COLL?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The largest risk is the pace of pain-portfolio decline. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $28.00, +13.3% from the $24.72 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for COLL?
+
Jornay PM share gains in ADHD. Jornay PM is the main growth asset. The most optimistic analyst target on COLL is $60.00, +142.7% from the $24.72 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for COLL?
+
The largest risk is the pace of pain-portfolio decline. Nucynta revenue fell 44% in a year once generics arrived, and a 2018 settlement allows Teva to sell a generic Belbuca from January 23, 2027 if it has FDA approval. Belbuca was about $222 million of 2025 revenue, so a launch would cut deeply into cash flow. Ascent Pharmaceuticals has also filed to challenge Belbuca's 2032 patent. Xtampza ER faces payer pressure. Opioid exposure brings legal risk: several dozen third-party payors sued Collegium and others in July 2026, alleging Nucynta and Xtampza ER were promoted to encourage continued prescribing, and several state attorneys general have open investigations. ADHD stimulants are Schedule II drugs, so DEA production quotas and shortages can limit supply. The balance sheet carries about $1.08 billion of debt plus a Jornay royalty obligation at about 13.5% effective interest, and cash fell from about $387 million at the end of 2025 to $145 million after the Azstarys purchase. Operating expenses rose 44% in the third quarter, and further acquisitions add integration risk. The stock is small and has been volatile, falling about 17% after the August report and about 45% so far in 2026. Analysts expect revenue of about $848 million in 2027 but adjusted EPS to fall about 5% to roughly $7.08, which reflects the Belbuca generic risk. The most pessimistic published target is $28.00, +13.3% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Collegium Pharmaceutical do?
+
US specialty drugmaker selling pain medicines and the ADHD treatments Jornay PM and Azstarys.
What would have to change for COLL to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Jornay PM share gains in ADHD) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the largest risk is the pace of pain-portfolio decline) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Collegium Pharmaceutical do?
+
Collegium is a US specialty pharmaceutical company that buys and sells approved branded drugs instead of running early-stage research. It has two franchises. The pain portfolio includes Belbuca, a buprenorphine film placed against the cheek; Xtampza ER, an abuse-deterrent extended-release oxycodone; and the Nucynta tapentadol products. The ADHD franchise includes Jornay PM, a methylphenidate taken in the evening, and Azstarys, acquired from Corium in May 2026. In the third quarter of 2026 the company reported $216.3 million of net product revenue, with pain products at about 64% and ADHD at about 36%. It sells through a specialty sales force of around 190 representatives in the US and has no meaningful international business.
How did Collegium do in the third quarter of 2026?
+
Revenue grew about 3% to a record $216.3 million, adjusted EBITDA fell about 9% to $121.6 million, and adjusted EPS was $1.96 against $2.25 a year earlier, above the analyst consensus by about 5.6%. GAAP net income was $21.8 million, or $0.60 per diluted share, helped by a tax benefit. Jornay PM revenue grew 24% to $51.9 million and Azstarys added $26.5 million, while pain revenue fell 18% to $138.0 million because Nucynta dropped 44%. Operating cash flow was $86.5 million. The company reaffirmed 2026 guidance of $825 million to $855 million of revenue and $445 million to $470 million of adjusted EBITDA, and the shares rose about 7% on the day of the report.
Why has COLL stock fallen so much?
+
The shares closed at about $25.03 on November 20, 2026, down about 45% year to date and 43% over a year. Three things weighed on them. Nucynta revenue fell sharply once generic and authorized-generic versions arrived, and the shares dropped about 17% after the August report on Nucynta pricing. The Azstarys deal used about $356 million of cash and a $300 million term loan, pushing debt above $1 billion, and higher operating costs mean adjusted EBITDA for 2026 is guided roughly flat with 2025 despite higher revenue. Investors are also weighing a possible generic Belbuca from Teva as early as January 23, 2027. The stock bottomed near $21.43 before the third-quarter report and has since recovered about 9% over the past month.
Walnut is informational, not investment advice, and gives no verdict on COLL. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.